CanSino Biologics (SEHK:6185) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

6185 Stoklara Genel Bakış

CanSino Biologics Inc. Çin Halk Cumhuriyeti'nde aşı geliştirmekte, üretmekte ve ticarileştirmektedir.

6185 temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Trading at 89.1% below our estimate of its fair value

Earnings are forecast to grow 117.56% per year

Risk Analizi

Risk kontrollerimizden 6185 için herhangi bir risk tespit edilmedi.

CanSino Biologics Inc. Rakipler

Shanghai Junshi Biosciences

SEHK:1877

HK$30.4b

AIM Vaccine

SEHK:6660

HK$10.8b

InnoCare Pharma

SEHK:9969

HK$13.9b

Jacobio Pharmaceuticals Group

SEHK:1167

HK$1.5b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti CanSino Biologics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$29.25
52 Haftanın En Yüksek Seviyesi	HK$29.15
52 Haftanın En Düşük Seviyesi	HK$14.80
Beta	0.52
11 Aylık Değişim	65.44%
3 Aylık Değişim	47.88%
1 Yıllık Değişim	39.95%
33 Yıllık Değişim	-87.32%
5 Yıllık Değişim	-16.07%
Halka arzdan bu yana değişim	-15.71%

Son Haberler & Güncellemeler

Recent updates

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Apr 07

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Feb 06

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Oct 13

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Sep 07

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Jul 13

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Jul 01

We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

Mar 15

CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

Jan 11

Hissedar Getirileri

	6185	HK Biotechs	HK Pazar
7D	39.3%	18.3%	8.7%
1Y	40.0%	1.9%	19.7%

Getiri vs. Endüstri: 6185 exceeded the Hong Kong Biotechs industry which returned 1.9% over the past year.

Getiri vs Piyasa: 6185 exceeded the Hong Kong Market which returned 19.7% over the past year.

Fiyat Oynaklığı

Is 6185's price volatile compared to industry and market?
6185 volatility
6185 Average Weekly Movement	8.7%
Biotechs Industry Average Movement	7.8%
Market Average Movement	7.1%
10% most volatile stocks in HK Market	14.7%
10% least volatile stocks in HK Market	3.6%

İstikrarlı Hisse Senedi Fiyatı: 6185's share price has been volatile over the past 3 months.

Zaman İçindeki Volatilite: 6185's weekly volatility (9%) has been stable over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2009	1,149	Xuefeng Yu	www.cansinotech.com

CanSino Biologics Inc. Çin Halk Cumhuriyeti'nde aşılar geliştirmekte, üretmekte ve ticarileştirmektedir. Şirket, rekombinant yeni koronavirüs hastalığına karşı Convidecia ve İnhalasyon aşıları için Ad5-nCoV; bir Ebola virüsü aşısı olan Ad5-EBOV; ve N. meningitides'in önlenmesi için MCV2 ve MCV4 aşılarını geliştirmektedir. Bebekler için DTcP aşısı ve birincil aşılamadan sonra boğmacayı önleyen zayıf korumayı ele almak için Faz I klinik çalışmasında olan DTcP Booster aşısını geliştirmektedir.

CanSino Biologics Inc. Temel Bilgiler Özeti

CanSino Biologics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
6185 temel i̇stati̇sti̇kler
Piyasa değeri	HK$10.76b
Kazançlar(TTM)	-HK$957.26m
Gelir(TTM)	HK$700.93m

10.3x

P/S Oranı

-7.5x

F/K Oranı

6185 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
6185 gelir tablosu (TTM)
Gelir	CN¥634.61m
Gelir Maliyeti	CN¥486.20m
Brüt Kâr	CN¥148.41m
Diğer Giderler	CN¥1.02b
Kazançlar	-CN¥866.68m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Oct 30, 2024

Hisse başına kazanç (EPS)	-3.51
Brüt Marj	23.39%
Net Kâr Marjı	-136.57%
Borç/Özkaynak Oranı	43.0%

6185 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

6185 Stoklara Genel Bakış

Ödüller

Risk Analizi

CanSino Biologics Inc. Rakipler

SEHK:1877

HK$30.4b

SEHK:6660

HK$10.8b

SEHK:9969

HK$13.9b

SEHK:1167

HK$1.5b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

CanSino Biologics Inc. to Report Q3, 2024 Results on Oct 30, 2024

Co-Founder recently bought HK$436k worth of stock

High number of new directors

Co-Founder recently bought HK$367k worth of stock

Consensus EPS estimates fall by 10%

Co-Founder recently bought HK$186k worth of stock

Recent updates

CanSino Biologics Inc. to Report Q3, 2024 Results on Oct 30, 2024

Co-Founder recently bought HK$436k worth of stock

High number of new directors

Co-Founder recently bought HK$367k worth of stock

Consensus EPS estimates fall by 10%

Co-Founder recently bought HK$186k worth of stock

Co-Founder recently bought HK$377k worth of stock

CanSino Biologics Inc. to Report First Half, 2024 Results on Aug 30, 2024

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

Consensus EPS estimates upgraded to CN¥1.19 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cansino Biologics Inc. Announces Positive Preliminary Results from Phase I Clinical Trials of the Protein-Based Pneumococcal Vaccine

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Full year 2023 earnings: EPS and revenues miss analyst expectations

CanSino Biologics Inc. to Report Q1, 2024 Results on Apr 30, 2024

Consensus EPS estimates upgraded to CN¥1.04 loss, revenue downgraded

Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine

Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case

Third quarter 2023 earnings released

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Second quarter 2023 earnings released: CN¥2.82 loss per share (vs CN¥0.44 loss in 2Q 2022)

New minor risk - Share price stability

CanSino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc. Announces CS-2032 Zoster Vaccine Obtains Clinical Trial Approval from Canada

CanSino Biologics Inc. to Report First Half, 2023 Results on Aug 22, 2023

Cansino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Full year 2022 earnings released: CN¥3.65 loss per share (vs CN¥7.74 profit in FY 2021)

Consensus EPS estimates fall by 49%

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Non-Executive Director recently sold HK$3.4m worth of stock

Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

Cansino Biologics Inc. Announces Covid-19 Mrna Vaccine Cs-2034 Achieved Positive Interim Data in A Clinical Trial Evaluating the Safety and Immunogenicity of the Heterologous Cs-2034 Booster

CanSino Biologics Inc. Announces Clinical Research Results of A Clinical Trial of Bivalent Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation in Adults Aged 18 Years and Above

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

Less than half of directors are independent

CanSino Biologics Inc.'s Recombinant Covid-19 Vaccine (Adenovirus Type 5Vector) for Inhalation Approved for Emergency Use in Morocco

Consensus EPS estimates fall by 73%

Consensus revenue estimates fall by 12%

Now 38% undervalued

Third quarter 2022 earnings released

Investor sentiment improved over the past week

CanSino Biologics Inc. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week